Corcept Therapeutics
CORT
228 hedge funds and large institutions have $1.84B invested in Corcept Therapeutics in 2022 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 72 increasing their positions, 83 reducing their positions, and 19 closing their positions.
116% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 19
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more call options, than puts
Call options by funds: $10.6M | Put options by funds: $7.43M
15% more capital invested
Capital invested by funds: $1.59B → $1.84B (+$242M)
10% more funds holding
Funds holding: 208 → 228 (+20)
7.02% more ownership
Funds ownership: 69.78% → 76.8% (+7%)
13% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 83
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$15.4M |
| 2 |
SG Americas Securities
New York
|
+$9.11M |
| 3 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$8.3M |
| 4 |
BlackRock
New York
|
+$8.01M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$6.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$33.3M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$10.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.63M |
| 4 |
Renaissance Technologies
New York
|
-$5.38M |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$4.29M |
CORT Hedge Fund Activity: Q1 2022 in Review
228 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2022, worth a combined $1.84B — up 15% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CORT positions and 19 closed out — a net gain of 22 holders — while 72 added to existing stakes and 83 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $15.4M. The largest seller was Millennium Management, cutting an estimated $33.3M.
- 228 institutional investors held Corcept Therapeutics (CORT) as of Q1 2022, up from 208 in Q4 2021.
- Funds reported $1.84B of Corcept Therapeutics stock for Q1 2022, up 15% quarter-over-quarter.
- 41 funds opened new Corcept Therapeutics positions in Q1 2022 and 19 closed out, a net change of +22 holders.
- The largest Corcept Therapeutics buyer in Q1 2022 was D.E. Shaw & Co, an estimated $15.4M added.
- The largest Corcept Therapeutics seller in Q1 2022 was Millennium Management, an estimated $33.3M sold.
Based on aggregated 13F filings for Q1 2022.